查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832331

輸血診斷市場（按產品、技術、最終用戶和應用）—2025-2032 年全球預測

Blood Transfusion Diagnostics Market by Product, Technology, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，輸血診斷市場將成長至 83.2 億美元，複合年成長率為 10.08%。

主要市場統計數據
基準年2024年 38.6億美元
預計2025年 42.5億美元
預測年份：2032年 83.2億美元
複合年成長率（%） 10.08%

對輸血診斷領域發展趨勢的策略性介紹以及及時洞察的重要性

診斷技術的發展和政策重點的轉變，使輸血安全成為醫療保健提供者、診斷開發人員和公共衛生組織的關鍵策略領域。核酸檢測、病原體去活化和血清學平台的快速創新正在重塑捐血篩檢和輸血安全的運作方式，提高了製造商和實驗室的供應鏈韌性和監管監控標準。因此，需要清晰全面地了解技術發展軌跡、細分市場動態和營運漏洞，以便做出保護病患和維持醫療連續性的決策。

本報告整合了監管更新、臨床應用模式、技術檢驗研究和採購行動的橫斷面證據，旨在為相關人員提供關於新興風險和機會的簡明方向。報告重點在於設備、耗材、試劑系統和檢測方式之間的相互作用，闡明漸進式改善如何帶來顯著的臨床和經濟效益。報告始終強調操作可行性、檢驗路徑以及診斷選擇與機構能力和公共衛生目標的一致性。

總之，引言為在複雜、快速變化的市場中導航的實用、循證方法奠定了基礎，在該市場中，患者安全、成本控制和技術差異化決定了競爭定位和公共健康影響。

技術採用、監管期望和營運模式的轉型正在重新定義輸血診斷

輸血診斷領域正在經歷多重相互促進的變革，這些變革正在改變產品開發、實驗室工作流程和籌資策略。在技​​術方面，核酸檢測已經成熟，同時強大的血清學平台和有針對性的病原體去活化方法也已成熟，從而能夠更可靠地檢測並降低輸血相關風險。這些技術進步也推動了對模組化儀器和整合試劑生態系統的需求，從而縮短了周轉時間，並支援在集中式和分散式檢測環境中實現更高的通量。

同時，監管要求也日益嚴格，監管機構優先考慮產品性能檢驗、上市後監管和可追溯性。這促使供應商需要投資於能夠經受嚴格監控的嚴格臨床驗證和品質系統。同時，營運模式正轉向醫院、獨立實驗室和研究機構之間的夥伴關係，強調基礎設施共用、整合採購和協作驗證研究。這種合作趨勢有利於實現規模經濟，同時允許小型機構透過外包服務和區域中心獲得先進的檢測能力。

財務壓力和供應鏈中斷促使企業更加重視韌性、多元化採購以及盡可能實現在地化生產。因此，市場現有企業和新參與企業正在重新平衡其產品組合，以整合符合不斷變化的臨床路徑和付款人期望的耗材、設備和試劑產品。總而言之，這些轉型變革正在增加複雜性，並為能夠將技術創新與檢驗的可擴展部署模型相結合的公司創造新的競爭優勢。

2025年美國宣布的關稅對輸血診斷供應鏈、成本和策略採購的累積影響

2025年實施的關稅對輸血診斷供應鏈產生了多方面的影響，影響了採購決策、成本結構和製造佈局。進口零件和設備關稅的提高，立即擠壓了依賴全球化製造網路的供應商的利潤空間，促使許多組織重新評估其供應商基礎和庫存策略。因此，採購團隊優先考慮擁有本地製造能力和/或多元化供應商網路的供應商，以降低波動性並避免單一來源的風險。

除了直接的成本影響外，關稅還加速了企業向關鍵零件（尤其是複雜儀器和大批量耗材）的近岸外包或逐步在岸外包的策略轉變。這項轉變正在影響資本配置和長期供應鏈設計，企業正在權衡更高的本地製造成本與降低地緣政治和物流風險之間的利弊。此外，關稅也促使一些實驗室和醫療系統重新談判契約，在臨床可接受的範圍內延長產品生命週期，並探索集團採購安排，以抵消短期價格壓力。

監管和報銷動態也與關稅的影響相互影響。公共和私人採購決策者在評估診斷系統時，越來越嚴格地審查總體擁有成本，包括生命週期支援和服務彈性。因此，能夠展現穩健服務模式、透明定價和靈活供應結構的供應商更有能力客戶維繫。同時，一些創新者正在加速試劑和耗材的設計和開發，透過模組化和互通性簡化供應鏈的複雜性，提供替代途徑，以減輕關稅主導的中斷風險​​。

以細分市場為中心的洞察，揭示產品類型、技術模式、最終用戶和應用細分市場中存在的策略曲折點

產品細分顯示耗材及配件、儀器、試劑及試劑套件之間的清晰分層，每種都有不同的商業動態和操作要求。微孔盤和微量吸管尖耗材及配件是大批量、成本敏感的物品，因此供應的連續性和品管至關重要，迫使買家優先考慮可靠的供應商和有效的品質系統。核酸分析儀、病原體去活化系統和血清學分析儀等儀器是資本密集型投資，使用壽命長，檢驗負擔重，因此有利於提供整合服務協議和可互通軟體的供應商。擴增試劑、抗體試劑和 DNA 萃取試劑套件等試劑和試劑套件將技術特異性與監管複雜性結合在一起，要求製造商保持嚴格的批間一致性，並對新病原體和檢測更新做出快速反應。

技術的細分進一步細分了開發商和買家的優先順序。核酸檢測方法，例如PCR、即時PCR和轉錄媒介增幅，具有較高的分析靈敏度，通常是病毒標記早期檢測的首選，但也需要訓練有素的人員和強大的檢測基礎設施。使用阿莫沙林、亞甲藍或核黃素的病原體去活化技術因其惰性血液成分中多種威脅的潛力而日益受到評估，其採用取決於已證實的臨床療效、工作流程相容性和成本效益。血清學檢測平台，包括CLIA、ELISA和橫向流動化驗，在免疫分析和篩檢工作流程中仍然至關重要，通量、特異性和照護現場之間的權衡驅動著採購決策。

最終用戶的細分——醫院血庫、獨立實驗室和研究機構——影響購買行為和服務期望。醫院血庫優先考慮營運的連續性、與臨床工作流程的兼容性以及在時間敏感條件下供應商的反應能力；而獨立實驗室通常更重視通量、檢測標準化以及支援多客戶的靈活設備空間。研究機構則傾向於優先考慮檢測的靈活性以及獲得新試劑和平台進行實驗檢驗的便利性，從而促進創新方法的早期採用，並將其轉化為常規篩檢。

應用類別（例如捐血篩檢、品管或輸血安全）決定了性能要求和驗證途徑。捐血篩檢任務（例如免疫血液學檢測和病毒標記篩檢）需要高靈敏度和特異性，以最大限度地降低輸血傳染感染疾病的風險。品管控制（包括外部能力驗證和內部品管）對於維持診斷準確性和法規遵循至關重要。輸血安全任務（例如血型鑑定和病原體去活化）需要可互通的工作流程和檢驗的儀器/試劑組合，以確保整個輸血鏈中的患者治療結果和可追溯性。

區域視角突顯全球市場獨特的招募模式、法規環境和業務重點

美洲地區擁有先進的實驗室基礎設施、完善的醫院網路，並在核酸檢測和病原體控制技術方面積極投入。該地區的醫療保健系統通常優先考慮快速部署、整合服務合約以及與電子健康記錄和血液管理平台的互通性。相關政策和採購機制強調檢驗的臨床性能和可追溯性，從而滿足了對全面的儀器和試劑生態系統以及強大的供應商支援模式的需求。

歐洲、中東和非洲是多元化市場，各地區監管環境、資金籌措模式和基礎建設成熟度差異顯著。在許多歐洲市場，嚴格的監管途徑和集中採購框架有利於擁有可靠合規性和跨境服務能力的供應商。中東市場正在投資升級其實驗室能力，有時透過官民合作關係關係進行。同時，非洲市場經常需要適應資源受限環境的解決方案，強調穩健性、易用性和較低的整體擁有成本。在全部區域，策略採用通常依賴當地檢驗研究、區域分銷網路和培訓計劃，以確保永續採用。

亞太地區的特點是診斷能力的快速現代化、充滿活力的本地製造生態系統以及不同經濟體之間差異化的採用曲線。該地區的一些市場以積極採用照護現場血清學檢測和可擴展核酸檢測平台而著稱，這得益於公共衛生計畫和不斷擴張的私人醫療網路。該地區的供應鏈優勢和政策重點加速了技術轉移和合作開發，但監管趨同和標準協調是持續存在的挑戰，影響跨境商業化策略。

競爭對手層面的動態塑造輸血診斷領域的競爭、合作與創新策略

例如，受訪的輸血診斷領域的公司正在尋求垂直整合、策略夥伴關係和選擇性專業化相結合的方式，以平衡規模優勢和技術差異化。提供整合儀器、試劑和服務的製造商可以透過簡化驗證途徑和確保端到端責任制，向大型機構投資者提供極具吸引力的價值提案。相反，專注於特定技術或試劑化學成分的專業公司通常能夠推動創新，並憑藉有針對性的功效和成本績效優勢吸引早期採用者。

診斷公司、學術中心和臨床網路之間的合作正日益成為加速檢測檢驗和擴大臨床接受度的機制。此類合作為真實世界證據的生成提供了可行的途徑，並能夠透過利用分散式臨床測試和共用數據平台來縮短從開發到應用的時間。同時，服務和分銷夥伴關係在擴大地理覆蓋範圍和確保供應連續性方面發揮關鍵作用，尤其是在基礎設施不均衡的地區。

投資模式表明，資金正被配置在自動化、數位連接和多重檢測領域。在以總擁有成本和營運韌性為關鍵採購標準的環境下，那些擁有強大售後支援、遠距離診斷能力和持續改善管道的公司更有能力留住客戶。總體而言，公司策略正圍繞著靈活性、臨床證據和供應可靠性——這些是競爭成功的關鍵決定因素——進行整合。

為產業領導者提供切實可行的建議，以加強輸血診斷領域的市場定位、彈性和臨床影響

企業應優先投資模組化平台和可互通的試劑生態系統，以減輕醫院實驗室的檢驗負擔，並促進其快速融入現有工作流程。透過設計既能滿足高通量集中式實驗室需求，又能滿足分散式檢查需求的解決方案，供應商可以擴大其潛在市場，並降低依賴單一通路帶來的風險。同時，改善服務模式，例如預測性維護、遠端監控和透明的生命週期成本揭露，可以增強買家信心，提升購買意願。

鑑於近期貿易政策的變化，企業應重新考慮策略採購和製造，以最佳化冗餘和本地回應能力。企業應評估近岸外包選項、雙重採購策略和庫存最佳化技術，以在控制成本的同時保持連續性。儘早與監管機構溝通並參與協調舉措，可以減少市場摩擦，並為跨境商業化開闢清晰的道路。重要的是，企業應與臨床網路和公共衛生組織建立合作夥伴關係，以產生真實世界證據，檢驗其性能並展示臨床效用。

最後，領導者應將資源分配給員工發展和變革管理，以確保臨床實施的順利進行。投資培訓模組、虛擬支援和協作檢驗專案可以降低實施風險並加速採用。透過實施這些建議，組織可以充分利用技術進步，同時保持營運彈性，並在輸血安全方面取得顯著改善。

對調查方法、數據三角測量過程以及分析所依據的檢驗通訊協定進行清晰的解釋

研究方法結合了對官方監管文件、同行評審臨床研究、專利申請和技術白皮書的系統綜述，以及實驗室主任、採購專業人員和診斷開發人員的結構化訪談。檢視了二手資訊的相關性和時效性，並進行了一手訪談，以了解從業人員對工作流程限制、驗證痛點和採購優先順序的見解。對這些輸入資料進行三角測量，以確定一致的主題並協調不同的觀點。

分析方法包括對訪談記錄進行定性編碼、整合監管指南以映射驗證要求，以及對敏感性、特異性、吞吐量和整合複雜性等技術屬性進行比較評估。情境分析檢驗了供應中斷和政策變化對營運的影響，敏感度檢驗則確保了結論在採用時間和採購行為的各種可能變化下依然穩健。在適當的情況下，我們開發了用例來說明實作路徑，並強調了從早期採用者那裡獲得的經驗教訓。

品質保證措施包括目標細分市場專家的同儕審查、技術聲明與監管文件和臨床文獻的交叉檢驗，以及透過相關人員的回饋不斷完善研究結果。原始資料收集過程中遵循倫理考量和保密保護原則，結論強調實際意義而非推測性預測。

結論：總結了輸血診斷領域的策略意義和相關人員的基本考慮因素。

輸血診斷領域正處於曲折點，技術進步、嚴格的監管環境和供應鏈現狀交織在一起，重新定義了機會和風險。相關人員若能協調產品開發和臨床檢驗需求，投資於彈性供應鏈架構，並優先考慮可互通的解決方案，將更有能力滿足機構和公共衛生的需求。由於儀器性能、試劑品質和營運支援之間的相互作用決定了實際影響，因此策略重點應放在證據生成、卓越服務和靈活的部署模式上。

此外，近期的政策發展和貿易行動凸顯了適應性籌資策略和區域合作的重要性。積極應對關稅相關漏洞、及早與監管機構溝通並與臨床網路建立合作夥伴關係關係的組織，可以減少實施摩擦並加速採用。總而言之，本部分認可規範的執行，即在技術創新與驗證、物流和臨床工作流程相容性等實際考量之間取得平衡。

此次整合旨在幫助決策者確定投資優先順序、最佳化籌資策略並設計實施方案，從而在管理成本和營運風險的同時提高輸血安全性。透過採用務實的數據主導方法，相關人員可以將技術進步與患者治療效果的可衡量改善聯繫起來。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 引入新一代核酸檢測平台，提高捐血病原體檢測靈敏度
  • 採用人工智慧和機器學習演算法，實現輸血中心血型分型和交叉配對檢查工作流程的自動化
  • 整合區塊鏈驅動的可追溯性解決方案，以確保血液供應鏈的安全並降低輸血相關的安全風險。
  • 擴大微流體照護現場診斷設備的應用，以便在緊急情況和農村地區進行快速床邊血液相容性檢測
  • 開發一種高性能多重免疫檢測，用於在捐贈者篩檢期間同時檢測多種輸血性行為感染

第6章 2025年美國關稅的累積影響

第7章 人工智慧的累積影響，2025年

第 8 章：輸血診斷市場（按產品）

  • 耗材及配件
    • 微孔盤
    • 微量吸管尖
  • 裝置
    • NAT分析儀
    • 病原體減少系統
    • 血清分析儀
  • 試劑和套件
    • 擴增試劑
    • 抗體試劑
    • DNA萃取試劑套件

9. 輸血診斷市場（依技術）

  • 核酸檢測
    • PCR
    • 即時PCR
    • 轉錄介導的擴增
  • 病原體減少技術
    • 阿莫托薩倫
    • 亞甲基藍
    • 核黃素
  • 血清學檢測
    • CLIA
    • ELISA
    • 橫向流動化驗

第 10 章。輸血診斷市場（按最終用戶）

  • 醫院血庫
  • 獨立實驗室
  • 研究所

第11章輸血診斷市場的應用

  • 捐血篩檢
    • 免疫血液學檢測
    • 病毒標記篩檢
  • 品管
    • 外部能力測試
    • 內部品管
  • 輸血安全
    • 血型測定
    • 病原體去活化

第 12 章：按地區分類的輸血診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章。輸血診斷市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。按國家/地區分類的輸血診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Ortho Clinical Diagnostics, Inc.
    • Grifols, SA
    • Thermo Fisher Scientific Inc.
    • Immucor, Inc.
    • Bio-Rad Laboratories, Inc.
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Siemens Healthineers AG
    • bioMerieux SA
Product Code: MRR-437D45958222

The Blood Transfusion Diagnostics Market is projected to grow by USD 8.32 billion at a CAGR of 10.08% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.86 billion
Estimated Year [2025] USD 4.25 billion
Forecast Year [2032] USD 8.32 billion
CAGR (%) 10.08%

Strategic introduction to the evolving blood transfusion diagnostics landscape and why timely insights matter

Advances in diagnostic technologies and shifting policy priorities have converged to make blood transfusion safety a critical strategic domain for healthcare providers, diagnostic developers, and public health agencies. Rapid innovations in nucleic acid testing, pathogen reduction, and serological platforms are reshaping how donation screening and transfusion safety are operationalized, while supply chain resilience and regulatory scrutiny are raising the bar for manufacturers and laboratories alike. Consequently, organizations need a clear, synthesized view of technological trajectories, segment dynamics, and operational vulnerabilities to make decisions that protect patients and maintain continuity of care.

This report synthesizes cross-cutting evidence from regulatory updates, clinical adoption patterns, technology validation studies, and procurement behavior to provide stakeholders with a concise orientation to emerging risks and opportunities. By highlighting the interplay between instrumentation, consumables, reagent systems, and testing modalities, the analysis illuminates where incremental improvements yield outsized clinical and economic benefits. Throughout, emphasis is placed on operational feasibility, validation pathways, and the alignment of diagnostic choices with institutional capacity and public health objectives.

In short, the introduction lays the groundwork for a pragmatic, evidence-driven approach to navigating a complex and fast-moving market where patient safety, cost containment, and technological differentiation determine competitive positioning and public health impact.

Transformative shifts in technology adoption, regulatory expectations, and operational models redefining transfusion diagnostics

The diagnostic landscape for blood transfusion is experiencing multiple, mutually reinforcing shifts that are transforming product development, laboratory workflows, and procurement strategies. On the technology front, the maturation of nucleic acid testing modalities alongside robust serological platforms and targeted pathogen reduction methods is enabling more reliable detection and mitigation of transfusion-related risks. These technical advances are accompanied by greater demand for modular instrumentation and integrated reagent ecosystems that reduce hands-on time and support higher throughput in centralized and decentralized testing environments.

Regulatory expectations are concurrently tightening, with authorities prioritizing validated performance, post-market surveillance, and traceability. This has intensified the need for suppliers to invest in rigorous clinical validation and quality systems that can withstand heightened scrutiny. At the same time, operational models are shifting toward partnerships between hospitals, independent laboratories, and research institutes that emphasize shared infrastructure, consolidated procurement, and joint validation studies. This collaborative trend supports economies of scale while enabling smaller facilities to access advanced testing capabilities through outsourced services or regional hubs.

Financial pressures and supply chain disruptions have encouraged a stronger emphasis on resilience, diversification of sourcing, and localized manufacturing where practicable. As a result, market incumbents and new entrants are rebalancing portfolios to integrate consumables, instruments, and reagent offerings that align with evolving clinical pathways and payer expectations. Taken together, these transformative shifts create both heightened complexity and new levers for competitive advantage for organizations that can align technological innovation with validated, scalable deployment models.

Cumulative implications of United States tariff measures announced in 2025 on supply chains, costs, and strategic sourcing in transfusion diagnostics

Tariff actions introduced in 2025 have had multifaceted repercussions across the supply chain for blood transfusion diagnostics, influencing sourcing decisions, cost structures, and manufacturing footprints. Increased duties on imported components and instruments have created immediate pressure on margins for suppliers that rely on globalized manufacturing networks, prompting many organizations to reassess their vendor base and inventory practices. As a result, procurement teams are prioritizing suppliers with localized production capabilities or diversified supplier networks to mitigate volatility and avoid single-source exposure.

In addition to direct cost effects, tariffs have accelerated strategic shifts toward nearshoring and incremental onshoring of critical components, particularly for complex instruments and high-volume consumables. This movement has implications for capital allocation and long-term supply chain design, with firms weighing the trade-offs between higher local manufacturing costs and reduced geopolitical and logistics risk. Furthermore, the tariffs have prompted some labs and health systems to renegotiate contracts, extend product lifecycles where clinically acceptable, and explore pooled purchasing agreements to offset short-term price pressures.

Regulatory and reimbursement dynamics also interact with tariff impacts. Decision-makers at public and private purchasers are increasingly scrutinizing total cost of ownership, including lifecycle support and service resilience, when evaluating diagnostic systems. Therefore, vendors that can demonstrate robust service models, transparent pricing, and flexible supply arrangements are better positioned to retain institutional customers. In parallel, some innovators have accelerated development of reagent and consumable designs that simplify supply chain complexity through modularity and interoperability, providing an alternate pathway to reduce exposure to tariff-driven disruptions.

Segment-focused insights that illuminate where product types, technology modalities, end users, and application areas create strategic inflection points

Product segmentation shows a clear stratification between consumables and accessories, instruments, and reagents and kits, each with distinct commercial dynamics and operational requirements. Consumables and accessories such as microplates and pipette tips are high-volume, cost-sensitive items where supply continuity and quality control are paramount, compelling purchasers to prioritize trusted suppliers and validated quality systems. Instruments, including nucleic acid testing analyzers, pathogen reduction systems, and serology analyzers, represent capital-intensive investments with long service lifecycles and significant validation burdens, which favor suppliers that offer integrated service contracts and interoperable software. Reagents and kits, spanning amplification reagents, antibody reagents, and DNA extraction kits, combine technical specificity with regulatory complexity, requiring manufacturers to maintain stringent lot-to-lot consistency and rapid responsiveness to emergent pathogens and assay updates.

Technology segmentation further refines priorities for developers and buyers. Nucleic acid testing modalities such as PCR, real-time PCR, and transcription-mediated amplification deliver high analytical sensitivity and are often preferred for early detection of viral markers, but they also require trained personnel and robust laboratory infrastructure. Pathogen reduction technologies employing amotosalen, methylene blue, or riboflavin are increasingly valued for their potential to inactivate a broad spectrum of threats in blood components, and their adoption hinges on demonstrated clinical efficacy, workflow compatibility, and cost-effectiveness. Serological testing platforms, including CLIA, ELISA, and lateral flow assays, remain critical for immune profiling and screening workflows, with trade-offs between throughput, specificity, and point-of-care applicability shaping procurement decisions.

End user segmentation - hospital blood banks, independent laboratories, and research institutes - influences purchasing behavior and service expectations. Hospital blood banks prioritize operational continuity, compatibility with clinical workflows, and supplier responsiveness under time-sensitive conditions, whereas independent laboratories often focus on throughput, assay standardization, and flexible instrument footprints that support multiple clients. Research institutes tend to prioritize assay flexibility and access to novel reagents and platforms for experimental validation, fostering early-stage adoption of innovative methods that can later be translated into routine screening.

Application segmentation - donation screening, quality control, and transfusion safety - determines performance requirements and validation pathways. Donation screening activities such as immunohematology testing and viral marker screening demand high sensitivity and specificity to minimize risk of transfusion-transmitted infections. Quality control practices that include external proficiency testing and internal quality control are essential for maintaining diagnostic accuracy and regulatory compliance. Transfusion safety tasks like blood group typing and pathogen inactivation require interoperable workflows and validated device-reagent pairings to ensure patient outcomes and traceability throughout the transfusion chain.

Regional perspectives highlighting distinct adoption patterns, regulatory climates, and operational priorities across global markets

The Americas region exhibits a combination of advanced laboratory infrastructure, well-established hospital networks, and active investment in both nucleic acid testing and pathogen mitigation technologies. Healthcare systems in this region often prioritize rapid deployment, integrated service agreements, and interoperability with electronic medical records and blood management platforms. Policy and procurement mechanisms emphasize validated clinical performance and traceability, which in turn supports demand for comprehensive instrument-reagent ecosystems and robust vendor support models.

Europe, Middle East & Africa present a heterogeneous landscape in which regulatory nuances, funding models, and infrastructure maturity vary considerably between territories. In many European markets, stringent regulatory pathways and centralized procurement frameworks favor suppliers with proven compliance track records and pan-border service capabilities. Middle Eastern markets are investing in upgrading laboratory capacities, sometimes through public-private partnerships, while African markets frequently require solutions adapted to constrained-resource settings, emphasizing ruggedness, ease of use, and lower total cost of ownership. Across this combined region, strategic adoption often depends on local validation studies, regional distribution networks, and training programs that ensure sustainable implementation.

Asia-Pacific is characterized by rapid modernization of diagnostic capabilities, active local manufacturing ecosystems, and heterogeneous adoption curves across economies. Some markets in the region are notable for aggressive adoption of point-of-care serological assays and scalable nucleic acid testing platforms, driven by both public health programs and expanding private healthcare networks. The region's supply chain strengths and policy priorities can accelerate technology transfer and collaborative development, but regulatory convergence and harmonized standards remain ongoing challenges that influence cross-border commercialization strategies.

Company-level dynamics shaping competition, collaboration, and innovation strategies within blood transfusion diagnostics

Competitors in the transfusion diagnostics space are pursuing a mix of vertical integration, strategic partnerships, and selective specialization to balance scale advantages with technological differentiation. Manufacturers that combine instruments, reagents, and service offerings can create compelling value propositions for large institutional buyers by simplifying validation pathways and ensuring end-to-end accountability. Conversely, specialized firms that focus on a narrow set of technologies or reagent chemistries often drive innovation and can capture early adopter segments through targeted efficacy and cost-performance advantages.

Collaborations between diagnostic firms, academic centers, and clinical networks are increasingly common as a mechanism to accelerate assay validation and broaden clinical acceptance. These alliances support pragmatic pathways to real-world evidence generation and can shorten the time from development to adoption by leveraging distributed clinical studies and shared data platforms. At the same time, service and distribution partnerships play a critical role in expanding geographic reach and ensuring supply continuity, particularly in regions with uneven infrastructure.

Investment patterns reveal that capital is being allocated toward automation, digital connectivity, and assay multiplexing, as buyers seek throughput gains and reduced hands-on time. Firms that demonstrate robust post-sale support, remote diagnostics capabilities, and continuous improvement pipelines are better positioned to retain customers in an environment where total cost of ownership and operational resilience are key purchasing criteria. Overall, company strategies are converging around flexibility, clinical evidence, and supply reliability as dominant determinants of competitive success.

Practical, actionable recommendations for industry leaders to strengthen market positioning, resilience, and clinical impact in transfusion diagnostics

Organizations should prioritize investments in modular platforms and interoperable reagent ecosystems that reduce validation burden for hospital laboratories and facilitate rapid integration into existing workflows. By designing solutions that accommodate both high-throughput central labs and decentralized testing scenarios, suppliers can expand addressable markets and mitigate risks associated with single-channel dependence. In parallel, enhancing service models with predictive maintenance, remote monitoring, and transparent lifecycle cost disclosures will increase buyer confidence and improve retention.

Strategic sourcing and manufacturing should be revisited in light of recent trade policy shifts to optimize for redundancy and regional responsiveness. Firms should evaluate nearshoring options, dual-sourcing strategies, and inventory optimization techniques to preserve continuity while controlling costs. Engaging early with regulatory authorities and participating in harmonization initiatives can reduce time-to-market friction and create clearer pathways for cross-border commercialization. Importantly, companies should cultivate collaborative partnerships with clinical networks and public health entities to generate real-world evidence that validates performance and demonstrates clinical utility.

Finally, leaders should allocate resources to workforce training and change management to ensure smooth clinical adoption. Investing in training modules, virtual support, and joint validation programs will reduce implementation risk and accelerate uptake. Executing these recommendations will position organizations to capitalize on technological advances while maintaining operational resilience and delivering measurable improvements in transfusion safety.

Transparent description of the research methodology, data triangulation processes, and validation protocols underpinning the analysis

The research approach combined systematic review of public regulatory documents, peer-reviewed clinical studies, patent filings, and technical white papers with structured interviews of laboratory directors, procurement specialists, and diagnostic developers. Secondary sources were vetted for relevance and recency, and primary interviews were conducted to capture practitioner insights on workflow constraints, validation pain points, and procurement priorities. Data were triangulated across these inputs to identify consistent themes and to reconcile divergent perspectives.

Analytical techniques included qualitative coding of interview transcripts, synthesis of regulatory guidance to map validation requirements, and comparative assessment of technology attributes such as sensitivity, specificity, throughput, and integration complexity. Scenario analysis was employed to examine the operational effects of supply disruptions and policy changes, while sensitivity checks ensured that conclusions remained robust across plausible variations in adoption timing and procurement behavior. Where appropriate, case studies were developed to illustrate implementation pathways and to highlight lessons learned from early adopters.

Quality assurance measures included peer review by subject matter experts, cross-validation of technical claims against regulatory filings and clinical literature, and iterative refinement of findings based on stakeholder feedback. Ethical considerations and confidentiality protections governed primary data collection, and conclusions emphasize practical implications rather than speculative forecasts.

Conclusion synthesizing strategic implications and the essential considerations for stakeholders navigating the transfusion diagnostics domain

The blood transfusion diagnostics landscape is at an inflection point where technical progress, regulatory rigor, and supply chain realities intersect to redefine opportunity and risk. Stakeholders that align product development with clinical validation needs, invest in resilient supply chain architectures, and prioritize interoperable solutions will be better positioned to meet institutional demands and public health imperatives. The interplay between instrument performance, reagent quality, and operational support determines real-world impact, and accordingly, strategic emphasis should be placed on evidence generation, service excellence, and flexible deployment models.

Moreover, recent policy developments and trade measures underscore the importance of adaptive sourcing strategies and regional engagement. Organizations that proactively address tariff-related vulnerabilities, engage regulators early, and build collaborative partnerships with clinical networks will reduce implementation friction and accelerate adoption. In sum, the sector rewards disciplined execution that balances innovation with practical considerations of validation, logistics, and clinical workflow compatibility.

This synthesis is intended to help decision-makers prioritize investments, refine procurement strategies, and design implementation plans that enhance transfusion safety while managing cost and operational risk. By adopting a pragmatic, data-driven approach, stakeholders can translate technological advances into measurable improvements in patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Implementation of next-generation nucleic acid testing platforms to enhance pathogen detection sensitivity in blood donations
  • 5.2. Adoption of artificial intelligence and machine learning algorithms for automated blood typing and crossmatching workflows in transfusion centers
  • 5.3. Integration of blockchain-enabled traceability solutions to secure the blood supply chain and mitigate transfusion-related safety risks
  • 5.4. Expansion of microfluidic point-of-care diagnostic devices for rapid bedside blood compatibility testing in emergency and rural settings
  • 5.5. Development of high-throughput multiplexed immunoassays for simultaneous detection of multiple transfusion-transmissible infections during donor screening

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Transfusion Diagnostics Market, by Product

  • 8.1. Consumables & Accessories
    • 8.1.1. Microplates
    • 8.1.2. Pipette Tips
  • 8.2. Instruments
    • 8.2.1. Nat Analyzers
    • 8.2.2. Pathogen Reduction Systems
    • 8.2.3. Serology Analyzers
  • 8.3. Reagents & Kits
    • 8.3.1. Amplification Reagents
    • 8.3.2. Antibody Reagents
    • 8.3.3. Dna Extraction Kits

9. Blood Transfusion Diagnostics Market, by Technology

  • 9.1. Nucleic Acid Testing
    • 9.1.1. Pcr
    • 9.1.2. Real Time Pcr
    • 9.1.3. Transcription Mediated Amplification
  • 9.2. Pathogen Reduction Technology
    • 9.2.1. Amotosalen
    • 9.2.2. Methylene Blue
    • 9.2.3. Riboflavin
  • 9.3. Serological Testing
    • 9.3.1. Clia
    • 9.3.2. Elisa
    • 9.3.3. Lateral Flow Assays

10. Blood Transfusion Diagnostics Market, by End User

  • 10.1. Hospital Blood Banks
  • 10.2. Independent Laboratories
  • 10.3. Research Institutes

11. Blood Transfusion Diagnostics Market, by Application

  • 11.1. Donation Screening
    • 11.1.1. Immunohematology Testing
    • 11.1.2. Viral Marker Screening
  • 11.2. Quality Control
    • 11.2.1. External Proficiency Testing
    • 11.2.2. Internal Quality Control
  • 11.3. Transfusion Safety
    • 11.3.1. Blood Group Typing
    • 11.3.2. Pathogen Inactivation

12. Blood Transfusion Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood Transfusion Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood Transfusion Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ortho Clinical Diagnostics, Inc.
    • 15.3.2. Grifols, S.A.
    • 15.3.3. Thermo Fisher Scientific Inc.
    • 15.3.4. Immucor, Inc.
    • 15.3.5. Bio-Rad Laboratories, Inc.
    • 15.3.6. Danaher Corporation
    • 15.3.7. F. Hoffmann-La Roche Ltd
    • 15.3.8. Abbott Laboratories
    • 15.3.9. Siemens Healthineers AG
    • 15.3.10. bioMerieux SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLOOD TRANSFUSION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLOOD TRANSFUSION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD TRANSFUSION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, 2018-2024 (USD MILLION)

TABLE 28